IMMGOTCFinancial Services · Financial - Conglomerates

Immage Biotherapeutics Corp.

$0.00+0.00%(+$0.00)

TickerSpark Score

49/100

Weak

100

Valuation

Profitability

Growth

Health

Momentum

Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a IMMG research report →

52-Week Range100% of range

Low $0.00

Current $0.00

High $0.00

Companywww.immagebio.com

Immage Biotherapeutics Corp. does not have significant business operations. Previously, it was engaged in developing novel immunotherapy biologics to treat various cancers in the United States.

CEO: Zhi Cong Mou
IPO: 2022
Employees: 3
HQ: Bethesda, US

Price Chart

+0.00% · this period

Valuation

Market Cap: $15.17K
P/E: -0.07
P/S: 0.00
P/B: 0.08
EV/EBITDA: 0.62
Div Yield: 0.00%

Profitability

Gross Margin: 0.00%
Op Margin: 0.00%
Net Margin: 0.00%
ROE: -200.39%
ROIC: -90.18%

Growth & Income

Revenue: $0 · 0.00%
Net Income: $-216,476 · -368269.47%
EPS: $-0.00 · -150.00%
Op Income: $-216,476
FCF YoY: -211688.55%

Performance & Tape

52W High: $0.00
52W Low: $0.00
50D MA: $0.00
200D MA: $0.00
Beta: 32.51
Avg Volume: 604.8

Get TickerSpark's AI analysis on IMMG

Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.

Get Pro Access →

30-day money-back guarantee · cancel anytime